Integra LifeSciences
IART
158 hedge funds and large institutions have $2B invested in Integra LifeSciences in 2014 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 57 increasing their positions, 51 reducing their positions, and 8 closing their positions.
225% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 8
12% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 51
10% more funds holding
Funds holding: 143 → 158 (+15)
3% less capital invested
Capital invested by funds: $2.06B → $2B (-$52.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CRM
Cramer Rosenthal McGlynn
Stamford,
Connecticut
|
+$8.38M |
| 2 |
Goldman Sachs
New York
|
+$7.89M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$7.39M |
| 4 |
TCM
Tributary Capital Management
Omaha,
Nebraska
|
+$4.68M |
| 5 |
SCM
Snow Capital Management
Sewickley,
Pennsylvania
|
+$4.32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$35.7M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$15M |
| 3 |
CI
Cambiar Investors
Denver,
Colorado
|
-$5.48M |
| 4 |
GAM
Gotham Asset Management
New York
|
-$5.4M |
| 5 |
ECP
Elk Creek Partners
Denver,
Colorado
|
-$3.17M |
IART Hedge Fund Activity: Q4 2014 in Review
158 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Integra LifeSciences (IART) for Q4 2014, worth a combined $2B — down 2.5% from $2.06B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new IART positions and 8 closed out — a net gain of 18 holders — while 57 added to existing stakes and 51 trimmed.
The largest buyer was Cramer Rosenthal McGlynn, opening a new position worth an estimated $8.38M. The largest seller was Invesco, cutting an estimated $35.7M.
- 158 institutional investors held Integra LifeSciences (IART) as of Q4 2014, up from 143 in Q3 2014.
- Funds reported $2B of Integra LifeSciences stock for Q4 2014, down 2.5% quarter-over-quarter.
- 26 funds opened new Integra LifeSciences positions in Q4 2014 and 8 closed out, a net change of +18 holders.
- The largest Integra LifeSciences buyer in Q4 2014 was Cramer Rosenthal McGlynn, an estimated $8.38M added.
- The largest Integra LifeSciences seller in Q4 2014 was Invesco, an estimated $35.7M sold.
Based on aggregated 13F filings for Q4 2014.